Join Fulcrum Therapeutics for a patient-focused webinar on sickle cell disease (SCD) and ongoing research into a potential new treatment. The program will include an overview of the Pioneer Study, which is evaluating pociredir, a once-daily oral therapy designed to increase fetal hemoglobin (HbF).
We will share updates on the 12-week data from the 20-milligram cohort. This is a follow-up from the presentation in September 2025 on the 12-milligram cohort.
The Pioneer study is currently in Phase 1b, which is exploring safety, efficacy, and dosage. Pociredir is in early stages of development.
Presenters include: Alex Sapir, President & CEO, Fulcrum Therapeutics; Iain Fraser, SVP, Head of Early Development Fulcrum Therapeutics; Martin H. Steinberg, MD, Professor, Boston Medical Center.


















































































































































































































































































